GH-axis research

CJC-1295 with DAC

Peptide lyophilisé de recherche de signalisation endocrinienne pour l'examen des systèmes

CJC-1295 with DAC is a longer-acting GHRH analog studied for extended GH-axis signaling and albumin-binding pharmacology.

98.6%-99.2% Poudre lyophilisée 5 mg

Available documentation

Support can confirm any currently available COAs or batch documentation for this product.

Request available documents

Quantité

Format du paquet

Effacer

Catalog updates and a welcome offer

Confirm an optional email signup to receive a single-use 10% welcome code.

Get catalog updates

Pour la recherche en laboratoire uniquement. Pas pour un usage humain ou vétérinaire. Non destiné à diagnostiquer, traiter, guérir, atténuer ou prévenir une maladie.

Stockage

Conserver scellé, froid, sec et protégé des variations de chaleur. Confirmez le stockage spécifique au produit à l'arrivée.

Notes d'expédition

Emballé pour la stabilité du transit avec une assistance aux commandes disponible pour les itinéraires par temps chaud.

Batch reference

Batch-linked certificate support is available through the documentation desk.

Contexte de recherche

Profil de recherche CJC-1295 with DAC

CJC-1295 with DAC is a longer-acting GHRH analog designed to extend exposure through drug-affinity-complex chemistry and albumin binding. Research examines pharmacokinetics, prolonged GH and IGF-1 marker changes, pituitary signaling, and how sustained activity differs from shorter GHRH analogs. It is distinct from CJC-1295 No DAC, which is used for shorter pulse-pattern comparisons, and from ipamorelin or GHRP compounds, which signal through the ghrelin receptor. This version is most relevant when half-life extension is central to the study design. Published pharmacology for named investigational material does not independently verify the sequence, purity, or performance of a catalog batch.

Molecular class

DAC-modified GHRH analog

Sequence / composition

A substituted GHRH 1-29-style peptide linked to a Drug Affinity Complex designed for albumin association.

Research design note

The DAC attachment, rather than the name alone, distinguishes the expected exposure profile from a no-DAC construct.

Mécanisme proposé

A GHRH analog containing a drug-affinity-complex group designed to form a covalent bond with serum albumin. Albumin binding reduces clearance and prolongs GHRH-receptor stimulation, increasing GH secretion and downstream IGF-1.

Effets rapportés dans les études

Healthy-adult studies reported dose-dependent increases in GH lasting several days and increases in IGF-1 lasting approximately one to two weeks after studied exposures.
Repeated exposure in pharmacology studies produced sustained elevation of GH and IGF-1 without eliminating pulsatile secretion.
Reported observations included injection-site reactions and endocrine changes expected from prolonged GH-axis stimulation.

Critères de recherche courants

Albumin binding, half-life, GHRH receptor activity, GH pulse pattern, integrated GH exposure, IGF-1, glucose, insulin, binding proteins, pharmacokinetics, and adverse events.

Preuves et limites

Controlled human pharmacology exists for the original investigational CJC-1295 with DAC. Product sequence and DAC chemistry must match before those data are considered relevant.

External reading

Literature for context—not product proof.

Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.

CJC-1295 with DAC PubMed literature search

Support and documentation

Questions about this product?

Where can I find product documentation?

Contact support with the product name and any relevant order or batch reference to request available documents.

How can I compare pack options?

Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.

Keep comparing

Compare other catalog records.

Explore related research materials. These are not a combined-use recommendation.